First Quadrant’s Neurocrine Biosciences NBIX Stock Holding History

First Quadrant’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,781	Closed	-$267K	–	644
2020 Q3	$267K	Buy	+2,781	New	+$322K	0.03%	303

Other funds holding NBIX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Quadrant's NBIX Position: Q4 2020 in Review

First Quadrant sold out of Neurocrine Biosciences (NBIX) in Q4 2020, closing a stake of 2,781 shares — an estimated $267K sold.

First Quadrant first reported a position in NBIX in Q3 2020 and held it in 1 quarter. The position peaked at $267K in Q3 2020. 406 funds tracked by Wall St. Rank hold NBIX as of Q4 2020.

First Quadrant reported no remaining Neurocrine Biosciences position as of Q4 2020 after selling out during the quarter.
First Quadrant sold 2,781 Neurocrine Biosciences shares in Q4 2020, an estimated $267K.
First Quadrant first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 1 quarter.
First Quadrant's Neurocrine Biosciences position peaked at $267K in Q3 2020.
406 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2020.

Based on First Quadrant's 13F filing for Q4 2020, filed 27 Jan 2021.